Advertisement

InflammoPharmacology

, Volume 11, Issue 3, pp 223–236 | Cite as

Peroxisome proliferator-activated receptor γ activation counters the detrimental effect of Helicobacter pylori lipopolysaccharide on gastric mucin synthesis

  • B. L. Slomiany
  • A. Slomiany
Article

Abstract

Peroxisome proliferator-activated receptor-γ (PPARγ), a member of the subfamily of ligand-dependent nuclear transcription factors, plays a key role in the regulation of the expression of genes associated with inflammation. In this study, using gastric mucosal cells in culture, we assess the role of PPARγ in the disturbances in gastric mucin synthesis and apoptotic processes evoked by Helicobacter pylori lipopolysaccharide (LPS). Exposure of gastric mucosal cells to the LPS led to a concentration-dependent decrease (up to 59.5%) in mucin synthesis, and this effect of the LPS was accompanied by a 6.5-fold increase in apoptosis, induction of COX-2 and NOS-2 protein expression, and the enhancement in PGE2 generation (18.6-fold) and NOS-2 activity (24.1-fold). However, the expression of COX-1 protein was not affected. Activation of PPARγ with a specific synthetic agonist, ciglitazone, countered (up to 90.2%) the LPS-induced reduction in mucin synthesis in a concentration-dependent manner, and this effect of the agent was reflected in a marked decrease in COX-2 and NOS-2 protein expression, reduction (up to 72.4%) in apoptosis and a decline (up to 84.1%) in PGE2 generation and NOS-2 activity (up to 90%). A pronounced prevention (88.2%) in the LPS-induced PGE2 release and the diminished COX-2 protein expression was also attained with the COX-2-selective inhibitor NS-398, but the effect was not associated with the impedance of the LPS inhibitory effect on mucin synthesis. Our findings thus demonstrate that the detrimental influence of H. pylori LPS on gastric mucin synthesis is closely linked to the increase in proapoptotic processes triggered by NOS-2 upregulation, and that PPARγ activation obviates this detrimental effect. Hence, pharmacological manipulation of PPARγ activation may provide therapeutic benefits in countering the disruptive effects of H. pylori on gastric mucosal mucus coat continuity.

Helicobacter pylori lipopolysaccharide gastric mucin synthesis PPARgamma activation NOS-2 COX-2 COX-1 apoptosis. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Brzozowski, T., Konturek, P. C., Sliwowski, Z., et al. (1997). Lipopolysaccharide of Helicobacter pylori protects gastric mucosa via generation of nitric oxide, J. Physiol. Pharmacol. 48, 699–717.Google Scholar
  2. Castrillo, A., de la Heras, B., Hortelano, S., et al. (2001). Inhibition of the nuclear factor кB (NF-кB) pathway by tetracyclic kaurene diterpenes in macrophages, J. Biol. Chem. 276, 15854–15860.Google Scholar
  3. Ceruda-Morollon, E., Pieneda-Molina, E., Canada, F. J., et al. (2001). 15-Deoxy-Δ12,14-prostaglandin J2 inhibition of NF-кB-DNA binding through covalent modification of the p50 subunit, J. Biol. Chem. 276, 35530–35536.Google Scholar
  4. Clancy, R., Varenika, B., Huang, W., et al. (2000). Nitric oxide synthase/ COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production, J. Immunol. 165, 1582–1587.Google Scholar
  5. Da Silva, J., Pierrat, B., Mary, J. L., et al. (1997). Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric oxide synthase expression in mouse astrocytes, J. Biol. Chem. 272, 28373–28380.Google Scholar
  6. de Boer, W. A. (2000). Topics in Helicobacter pylori infection: focus on a ‘search-and-treat’ strategy for ulcer disease, Scand. J. Gastroenterol. 35 (Suppl. 232), 4–9.Google Scholar
  7. DuBois, R. N., Abramson, S. B., Crofford, L., et al. (1998). Cyclooxygenase in biology and disease, FASEB J. 12, 1063–1073.Google Scholar
  8. Forman, B. M., Chen, J. and Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ, Proc. Natl. Acad. Sci. USA 94, 4312–4317.Google Scholar
  9. Fu, S., Ramanujam, K. S., Wong, A., et al. (1999). Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase-2 in Helicobacter pylori gastritis, Gastroen-terology 116, 1319–1329.Google Scholar
  10. Gorgoni, B., Caivano, M., Arzimendi, C., et al. (2001). The transcriptionalfactor C/EBPβ is essential for inducible expression of cox-2 gene in macrophages but not in fibroblasts, J. Biol. Chem. 276, 40769–40777.Google Scholar
  11. Gupta, R. A., Polk, D. B., Krishna, U., et al. (2001). Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor kB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells, J. Biol. Chem. 276, 31059–31066.Google Scholar
  12. Hawkey, C. J. (2002). Cyclooxygenase inhibition: between the devil and the deep blue sea, Gut 50 (Suppl. 3), 25–30.Google Scholar
  13. Hughes, F. J., Buttery, L. D. K., Hukkanen, M. V. J., et al. (1999). Cytokine-induced prostaglandin E2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and-independent mechanism in rat osteoblasts in vitro, J. Biol. Chem. 274, 1776–1782.Google Scholar
  14. Inoue, H., Tanabe, T. and Umesone, K. (2000). Feedback control of cyclooxygenase expression through PPARγ, J. Biol. Chem. 275, 28028–28032.Google Scholar
  15. Jackson, L. M., Wu, K. C., Mahida, Y. R., et al. (2000). Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa, Gut 47, 762–770.Google Scholar
  16. Kim, S. J., Ju, J. W., Oh, C. D., et al. (2002). ERK1/ 2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in associationwith p53 and caspse-3, and differentiationstatus, J. Biol. Chem. 277, 1332–1339.Google Scholar
  17. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacterio-phage T4, Nature 227, 680–685.Google Scholar
  18. Laine, L. (2001). Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient, Gastroenterology 120, 594–606.Google Scholar
  19. Liau, Y. H., Lopez, R. A., Slomiany, A., et al. (1992). Helicobacter pylori effect on the synthesis and secretion of sulfated gastric mucin, Biochem. Biophys. Res. Commun. 184, 1411–1417.Google Scholar
  20. Marnett, L. J., Wright, T. L., Crews, B. C., et al. (2000). Regulation of prostaglandin biosynthesis by nitric oxide is revealed by target deletion of inducible nitric-oxide synthase, J. Biol. Chem. 275, 13427–13430.Google Scholar
  21. Marshall, B. J. (1994). Helicobacter pylori, Am. J. Gastroenterol. 89, S116–S128.Google Scholar
  22. Nakajima, A., Wada, K., Miki, H., et al. (2001). Endogenously PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusioninjury, Gastroenterology 120, 460–469.Google Scholar
  23. Piotrowski, J. (1998). Lipopolysaccharidea virulence factor of Helicobacter pylori: effect of antiulcer agents, J. Physiol. Pharmacol. 49, 3–24.Google Scholar
  24. Piotrowski, J., Piotrowski, E., Skrodzka, D., et al. (1997). Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide, Scand. J. Gastroenterol. 32, 203–211.Google Scholar
  25. Poligone, B. and Baldwin, A. S. (2001). Positive and negative regulation of NF-кB by COX-2, J. Biol. Chem. 276, 38658–38664.Google Scholar
  26. Ratovitski, E. A., Bao, C., Quick, R. A., et al. (1999). An inducible nirtric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity, J. Biol. Chem. 274, 30250–30257.Google Scholar
  27. Romano, M., Ricci, V., Memoli, A., et al. (1998). Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro, J. Biol. Chem. 273, 28560–28563.Google Scholar
  28. Sakamoto, J., Kimura, H., Moriyama, S., et al. (2000). Activation of human peroxisome proliferator-activated receptor (PPAR) Subtypes by pioglitazone, Biochem. Biophys. Res. Commun. 278, 704–711.Google Scholar
  29. Shakibaei, M., Schulze-Tanzil, G., deSouza, P., et al. (2001). Inhibition of mitogen-activated protein kinase induced apoptosis of human chondrocytes, J. Biol. Chem. 276, 1389–1394.Google Scholar
  30. Slomiany, B. L. and Slomiany, A. (1991). Role of mucus in gastric mucosal protection, J. Physiol. Pharmacol. 42, 147–161.Google Scholar
  31. Slomiany, B. L. and Slomiany, A. (2001). Blockade of p38 mitogen-activatedprotein kinase pathway inhibits inducible nitric oxide synthase and gastric mucosal inflammatory reaction to Helicobacter pylori lipopolysaccharide, Inflammopharmacology 8, 371–382.Google Scholar
  32. Slomiany, B. L. and Slomiany, A. (2002). Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharideby peroxisome proliferator-activatedreceptor γ activation, IUBMB Life 53, 303–308.Google Scholar
  33. Slomiany, B. L., Liau, H., Lopez, R. A., et al. (1993). Nitecapone effect on the synthesis and secretion of gastric sulfomucin, Gen. Pharmacol. 24, 69–73.Google Scholar
  34. Slomiany, B. L., Murty, V. L. N., Piotrowski, E., et al. (1994). Activation of arachidonly phospholipase A2 in prostaglandin-mediatedaction of sucralfate, Gen. Pharmacol. 25, 261–266.Google Scholar
  35. Slomiany, B. L., Piotrowski, J. and Slomiany, A. (1997). Anti-Helicobacter pylori activities of ebrotidine, Arzneim. Forsch.-Drug Res. 47, 475–482.Google Scholar
  36. Tanaka, T., Kohno, H., Yoshitani, S., et al. (2001). Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats, Cancer Res. 61, 2424–2428.Google Scholar
  37. Warner, T. D., Giuliano, F., Vojnovic, I., et al. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather that cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. USA 96, 7563–7568.Google Scholar
  38. Wilson, K. T., Fu, S., Ramanujam, K. S. and Meltzer, S. J. (1998). Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas, Cancer Res. 58, 2929–2934.Google Scholar
  39. Xin, X., Yang, S., Kowalski, J., et al. (1999). Peroxisome proliferator-activatedreceptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo, J. Biol. Chem. 274, 9116–9121.Google Scholar
  40. Yu, S., Cao, W. Q., Kashireddy, P., et al. (2001). Human peroxisome proliferator-activatedreceptor α.PPARα) supports the induction of peroxisome proliferation in PPARα-deficient mouse liver, J. Biol. Chem. 276, 42485–42491.Google Scholar

Copyright information

© VSP 2003 2003

Authors and Affiliations

  • B. L. Slomiany
    • 1
  • A. Slomiany
  1. 1.Research Center, Room C875University of Medicine and Dentistry of New Jersey, 110USA

Personalised recommendations